Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study

Haematologica. 2015 May;100(5):e207-10. doi: 10.3324/haematol.2014.118182. Epub 2015 Jan 16.
No abstract available

Keywords: MM patients; intravenous bortezomib; relapsed multiple myeloma; renally impaired.

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Administration, Intravenous
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Boronic Acids / administration & dosage*
  • Boronic Acids / adverse effects
  • Bortezomib
  • Humans
  • Multiple Myeloma / complications
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / mortality
  • Multiple Myeloma / pathology*
  • Neoplasm Recurrence, Local
  • Pyrazines / administration & dosage*
  • Pyrazines / adverse effects
  • Renal Insufficiency / etiology
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Bortezomib

Associated data

  • ClinicalTrials.gov/NCT00722566